Trimethylamine N-oxide – 1 g

Brand:
Cayman
CAS:
1184-78-7
Storage:
-20
UN-No:
Non-Hazardous - /

Trimethylamine N-oxide (TMAO) is a metabolite of choline, phosphatidylcholine, and L-carnitine (Item No. 21489).{54307} It is formed by gut microbiota-mediated metabolism of choline, phosphatidylcholine, and L-carnitine to TMA followed by oxidation of TMA by flavin-containing monooxygenase 3 (FMO3) in the liver.{54307,54308,32692} Dietary administration of TMAO (0.12% w/w) increases renal tubulointerstitial fibrosis, collagen deposition, and Smad3 phosphorylation in mice and increases aortic lesion area in atherosclerosis-prone ApoE-/- mice.{54307,54309} Plasma levels of TMAO are elevated in patients with chronic kidney disease and decreased in patients with active, compared with inactive, ulcerative colitis.{54307,54308} Elevated plasma levels of TMAO are associated with increased risk of cardiovascular disease.{54309}  

 

Available on backorder

SKU: - Category:

Description

A metabolite of choline, phosphatidylcholine, and L-carnitine; dietary administration increases renal tubulointerstitial fibrosis, collagen deposition, and Smad3 phosphorylation in mice and increases aortic lesion area in atherosclerosis-prone ApoE-/- mice at 0.12% w/w; plasma levels of TMAO are elevated in patients with chronic kidney disease and decreased in patients with active, compared with inactive, ulcerative colitis; elevated plasma levels of TMAO are associated with increased risk of cardiovascular disease


Formal name: N,N-dimethyl-methanamine, N-oxide

Synonyms:  NSC 408426|TMAO

Molecular weight: 75.1

CAS: 1184-78-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Kidney & Renal Disease|Chronic Kidney Disease||Research Area|Endocrinology & Metabolism|Bile Acids & Microbiome||Research Area|Immunology & Inflammation|Gastric Disease|Ulcerative Colitis